Aberrant expression of PHF19 has been implicated in regulating the pathogenesis and progression of a wide range of cancers, including melanoma (Ghislin et al., 2012), hepatocellular carcinoma (Xu et al., 2015; Cai et al., 2018), glioma (Lu et al., 2018), glioblastoma (Deng et al., 2018), multiple myeloma (Ren et al., 2019). This evidence concerns the gene PHF19 and central nervous system cancer.